Dupilumab for asthma and wheezing in young children
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 2 and just under 6 years old.
- Your child has been diagnosed with asthma or severe wheezing that is not controlled with their current inhaler, which they have been using for at least 3 months.
- Your child has at least one of the following: doctor-diagnosed eczema, a known allergy to something in the air (like pollen or dust mites), wheezing when not sick, high eosinophils (a type of white blood cell) on a blood test, or a known food allergy to milk, egg, or peanut.
- Your child weighs more than about 11 pounds and less than about 66 pounds.
- Your child has not needed daily oral steroids for asthma for more than 1 month at a time.
- Your child was not born before 34 weeks of pregnancy.
- Your child does not have another chronic lung disease like cystic fibrosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.
This study tests whether dupilumab improves how well mucus is cleared from the airways in adults with moderate to severe asthma. It may help find better ways to reduce mucus-related breathing problems in people with a specific asthma type.
This trial tests if a new medicine, depemokimab, can help children aged 6 to 11 whose asthma is not well controlled with their current inhalers and who have a type of inflammation called eosinophilic asthma. It may reduce asthma attacks and improve symptoms.
This study follows children with wheezing (in younger kids) or doctor-diagnosed asthma (in older kids). It aims to better understand asthma and related breathing problems and how they develop over time.
This study tests if tezepelumab can help reduce severe asthma attacks in children ages 5 to 11. It compares the drug to a placebo (a dummy treatment) to see if it is safe and effective.
This trial tests if dupilumab can help young children with eosinophilic esophagitis (EoE), a condition that causes swelling in the esophagus. It may reduce symptoms and improve how the esophagus heals.
Hear when a new Wheezing trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.